Sensus Healthcare on the Q1 2026 Track: CPT Codes, Cash, and a Tale of Two Revenue Realities
Snapshot: revenue, cash, and customer mix
Sensus Healthcare, Inc. (Nasdaq: SRTS) reported its first quarter ended March 31, 2026 with revenue of $3.4 million, a sharp drop from $8.3 million in the year-ago period. Excluding the company’s historically largest customer, revenue would have been $2.7 million year over year. The company finished the quarter with $18.3 million in cash and no debt—an asset base that buys time but not a fiscal excuse when unit economics are still under the microscope.
Product shipments totaled 14 SRT systems in the quarter (10 direct sales and 4 under Fair Deal arrangements or rental) versus 30 systems shipped in the prior-year period (21 direct sales and 9 under Fair Deal). Importantly, none of the quarter’s direct sales were to the largest customer, compared with 15 such sales in the prior-year period, underscoring a notable shift in customer concentration.
Regulatory tailwinds and demand signals
Management noted that dedicated CPT codes for SRT and IG-SRT, effective January 1, 2026, provide reimbursement certainty for the treatment of non-melanoma skin cancer. The company said this change coincided with heightened inquiries, a stronger sales pipeline, and greater engagement from dermatology practices and hospitals after the code introduction.
Operational context: expansion and activation
The Fair Deal Agreement program continued to grow, with treatment volumes up 8% versus the first quarter of 2025. As of March 31, 2026, Sensus reported 18 active sites and 9 sites pending activation, a dynamic mix that suggests more installation activity on the horizon—if demand translates into revenue.
Forward-looking themes and sector implications
If the CPT-code tailwind persists, and the pipeline continues to mature, SRTS could begin to show more meaningful unit economics even as the headline revenue remains volatile. The cash position provides management optionality to navigate product launches, working-capital needs, or potential strategic moves in the sector.
For peers in the field, the lesson is straightforward: reimbursement clarity and code coverage can materially alter demand trajectories for niche diagnostic and treatment devices. Companies with diversified customer bases and scalable deployment models may be better positioned to weather quarterly revenue flux, while those tethered to a single large account could face more pronounced volatility.
What investors will watch next
Key metrics to monitor include EPS, EPS consensus, and any formal revenue forecast updates. The current release does not provide an EPS figure, so investors will look to upcoming quarters to gauge profitability momentum. In the near term, margin progression, utilization of the cash balance, and the pace at which the installed base converts to sustainable revenue will be critical gauges.
Conclusion: a cautious, clarifying quarter
The Q1 2026 print reads as a cautious, clarifying step rather than a decisive turnaround. CPT-code clarity and a growing, albeit still modest, installed base give SRTS a plausible path toward improved economics, but the challenge remains converting that into durable earnings power. For sector peers, the message is that reimbursement timing and payer certainty can meaningfully influence demand curves—even when the top-line numbers look softer. If Sensus can translate pipeline activity into revenue growth and margin expansion, the next few quarters might reveal a clearer trajectory toward profitability—and perhaps a healthier appetite for growth among investors watching the sector’s multiples tighten or loosen in response to regulatory clarity.